Abstract

An unique element of bladder urothelium is a multilayer membrane, which extends from the renal pelvis to the urethra. Urotelial membrane covers more than 90% of the inner portion of the bladder and is in direct contact with urine. Urothelium is composed of characteristic two-dimensional, asymmetric plaques, composed of uroplakins (UP), differentiated, hexagonally arranged proteins. The unique structure of the urothelial plaques determines the tightness, integrity and strength of the urothelium, prevent rupture of the walls of the bladder during the build-up of urine in the bladder and protects against the toxic ingredients. Uroplakins are tissue-specific, heterogeneous glycoproteins whose oligosaccharide part plays a specific role in the structure and function of urothelium. Disorders of normal expression of uroplakins are highly associated with the pathogenesis in infection and urinary tract malignancies, primary vesico-urinary reflux, hydronephrosis and renal impairment. The emergence of uroplakins in urine and / or plasma may have a potential role in the early detection of bladder tumors. In this paper, the structure and function of uroplakins types Ia, Ib, II, IIIa, their natural oligomerization into heterodimers, tetramers and hexamers, and the role in the construction of asymmetric and flexible urothelial epithelium is presented. We discuss the potential role of uroplakins in laboratory diagnosis of umbrella cell differentiation and in the screening analysis of urinary bladder disorders. The possibilities of using the knowledge of uroplakins in clinical settings as well as in modern strategies for treatment of infectious diseases and cancer of the urinary tract are highlighted.

References

• 1. Abgottspon D., Ernst B.: In vivo evaluation of FimH antagonists- a novel class of antimicrobials for the treatment of urinary tractinfection. Chimia, 2012; 66: 166-169
  Google Scholar
• 2. Abgottspon D., Rölli G., Hosch L., Steinhuber A., Jiang X., SchwardtO., Cutting B., Smiesko M., Jenal U., Ernst B., Trampuz A.: Developmentof an aggregation assay to screen FimH antagonists. J. Microbiol.Methods, 2010; 82: 249-255
  Google Scholar
• 3. Aboushwareb T., Zhou G., Deng F.M., Turner C., Andersson K.E.,Tar M., Zhao W., Melman A., D’Agostino R. Jr., Sun T.T., Christ G.J.:Alterations in bladder function associated with urothelial defectsin uroplakin II and IIIa knockout mice. Neurourol. Urodyn., 2009;28: 1028-1033
  Google Scholar
• 4. Acharya P., Beckel J., Ruiz W.G., Wang E., Rojas R., Birder L., ApodacaG.: Distribution of the tight junction proteins ZO-1, occludin,and claudin-4, -8, and -12 in bladder epithelium. Am. J. Physiol. RenalPhysiol., 2004; 287: F305-F318
  Google Scholar
• 5. Adachi W., Okubo K., Kinoshita S.: Human uroplakin Ib in ocularsurface epithelium. Invest. Ophthalmol. Vis. Sci., 2000; 41: 2900-2905
  Google Scholar
• 6. Albadine R., Schultz L., Illei P., Ertoy D., Hicks J., Sharma R., EpsteinJ.I., Netto G.J.: PAX8 (+)/p63 (-) immunostaining pattern in renalcollecting duct carcinoma (CDC): a useful immunoprofile in thedifferential diagnosis of CDC versus urothelial carcinoma of upperurinary tract. Am. J. Surg. Pathol., 2010; 34: 965-969
  Google Scholar
• 7. Anderson G.G., Dodson K.W., Hooton T.M., Hultgren S.J.: Intracellularbacterial communities of uropathogenic Escherichia coli inurinary tract pathogenesis. Trends Microbiol., 2004; 12: 424-430
  Google Scholar
• 8. Anderson G.G., Palermo J.J., Schilling J.D., Roth R., Heuser J., HultgrenS.J.: Intracellular bacterial biofilm-like pods in urinary tractinfections. Science, 2003; 301: 105-107
  Google Scholar
• 9. Apodaca G.: The uroepithelium: not just a passive barrier. Traffic,2004; 5: 117-128
  Google Scholar
• 10. Baza danych UniProt: www.uniprot.org/uniprot/?query=uroplakin&sort=score(25.02.2014)
  Google Scholar
• 11. Bishop B.L., Duncan M.J., Song J., Li G., Zaas D., Abraham S.N.:Cyclic AMP-regulated exocytosis of Escherichia coli from infectedbladder epithelial cells. Nat. Med., 2007; 13: 625-630
  Google Scholar
• 12. Bouckaert J., Berglund J., Schembri M., De Genst E., Cools L.,Wuhrer M., Hung C.S., Pinkner J., Slättegård R., Zavialov A., ChoudhuryD., Langermann S., Hultgren S.J., Wyns L., Klemm P. i wsp.: Receptorbinding studies disclose a novel class of high-affinity inhibitors ofthe Escherichia coli FimH adhesin. Mol. Microbiol., 2005; 55: 441-455
  Google Scholar
• 13. Bouckaert J., Mackenzie J., de Paz J.L., Chipwaza B., ChoudhuryD., Zavialov A., Mannerstedt K., Anderson J., Piérard D., Wyns L.,Seeberger P.H., Oscarson S., De Greve H., Knight S.D.: The affinity ofthe FimH fimbrial adhesin is receptor-driven and quasi-independentof Escherichia coli pathotypes. Mol. Microbiol., 2006; 61: 1556-1568
  Google Scholar
• 14. Butnor K.J., Ordonez N.G.: Uroplakin is not a reliable immunohistochemicalmarker for malignant mesothelioma of the pleura. Appl.Immunohistochem. Mol. Morphol., 2008; 16: 326-328
  Google Scholar
• 15. Chang A., Hammond T.G., Sun T.T., Zeidel M.L.: Permeabilityproperties of the mammalian bladder apical membrane. Am. J. Physiol.,1994; 267: C1483-C1492
  Google Scholar
• 16. Chen Y., Guo X., Deng F.M., Liang F.X., Sun W., Ren M., Izumi T.,Sabatini D.D., Sun T.T., Kreibich G.: Rab27b is associated with fusiformvesicles and may be involved in targeting uroplakins to urothelialapical membranes. Proc. Natl. Acad. Sci. USA, 2003; 100: 14012-14017
  Google Scholar
• 17. Chopra B., Hinley J., Oleksiewicz M.B., Southgate J.: Trans-speciescomparison of PPAR and RXR expression by rat and human urothelialtissues. Toxicol. Pathol., 2008; 36: 485-495
  Google Scholar
• 18. Chuang A.Y., DeMarzo A.M., Veltri R.W., Sharma R.B., BieberichC.J., Epstein J.I.: Immunohistochemical differentiation of high-gradeprostate carcinoma from urothelial carcinoma. Am. J. Surg. Pathol.,2007; 31: 1246-1255
  Google Scholar
• 19. Copp H.L., Chin J.L., Conaway M., Theodorescu D.: Prospectiveevaluation of the prognostic relevance of molecular staging for urothelialcarcinoma. Cancer, 2006; 107: 60-66
  Google Scholar
• 20. Deng F.M., Liang F.X., Tu L., Resing K.A., Hu P., Supino M., HuC.C., Zhou G., Ding M., Kreibich G., Sun T.T.: Uroplakin IIIb, a urothelialdifferentiation marker, dimerizes with uroplakin Ib as an earlystep of urothelial plaque assembly. J. Cell Biol., 2002; 159: 685-694
  Google Scholar
• 21. Desalle R., Chicote J.U., Sun T.T., Garcia-España A.: Generation ofdivergent uroplakin tetraspanins and their partners during vertebrateevolution: identification of novel uroplakins. BMC Evol. Biol.,2014; 14: 13
  Google Scholar
• 22. Duncan M.J., Li G., Shin J.S., Carson J.L., Abraham S.N.: Bacterialpenetration of bladder epithelium through lipid rafts. J. Biol. Chem.,2004; 279: 18944-18951
  Google Scholar
• 23. Foxman B., Brown P.: Epidemiology of urinary tract infections:transmission and risk factors, incidence, and costs. Infect. Dis. Clin.North Am., 2003; 17: 227-241
  Google Scholar
• 24. Garcia-España A., Chung P.J., Zhao X., Lee A., Pellicer A., Yu J.,Sun T.T., Desalle R.: Origin of the tetraspanin uroplakins and theirco-evolution with associated proteins: implications for uroplakinstructure and function. Mol. Phylogenet. Evol., 2006; 41: 355-367
  Google Scholar
• 25. Gulmann C., Paner G.P., Parakh R.S., Hansel D.E., Shen S.S., RoJ.Y., Annaiah C., Lopez-Beltran A., Rao P., Arora K., Cho Y., Herrera–Hernandez L., Alsabeh R., Amin M.B.: Immunohistochemical profileto distinguish urothelial from squamous differentiation in carcinomasof urothelial tract. Hum. Pathol., 2013; 44: 164-172
  Google Scholar
• 26. Hauser P.J., Dozmorov M.G., Bane B.L., Slobodov G., Culkin D.J.,Hurst R.E.: Abnormal expression of differentiation related proteinsand proteoglycan core proteins in the urothelium of patients withinterstitial cystitis. J. Urol., 2008; 179: 764-769
  Google Scholar
• 27. Hu C.C., Bachmann T., Zhou G., Liang F.X., Ghiso J., Kreibich G.,Sun T.T.: Assembly of a membrane receptor complex: roles of theuroplakin II prosequence in regulating uroplakin bacterial receptoroligomerization. Biochem. J., 2008; 414: 195-203
  Google Scholar
• 28. Hu P., Deng F.M., Liang F.X., Hu C.M., Auerbach A.B., Shapiro E.,Wu X.R., Kachar B., Sun T.T.: Ablation of uroplakin III gene resultsin small urothelial plaques, urothelial leakage, and vesicoureteralreflux. J. Cell Biol., 2000; 151: 961-972
  Google Scholar
• 29. Hu P., Meyers S., Liang F.X., Deng F.M., Kachar B., Zeidel M.L., SunT.T.: Role of membrane proteins in permeability barrier function:uroplakin ablation elevates urothelial permeability. Am. J. Physiol.Renal Physiol., 2002; 283: F1200-F1207
  Google Scholar
• 30. Huang H.Y., Shariat S.F., Sun T.T., Lepor H., Shapiro E., HsiehJ.T., Ashfaq R., Lotan Y., Wu X.R.: Persistent uroplakin expression inadvanced urothelial carcinomas: implications in urothelial tumorprogression and clinical outcome. Hum. Pathol., 2007; 38: 1703-1713
  Google Scholar
• 31. Hudoklin S., Jezernik K., Neumüller J., Pavelka M., Romih R.:Urothelial plaque formation in post-Golgi compartments. PLoS One,2011; 6: e23636
  Google Scholar
• 32. Jemal A., Siegel R., Xu J., Ward E.: Cancer statistics, 2010. CACancer J. Clin., 2010; 60: 277-300
  Google Scholar
• 33. Jenkins D., Bitner-Glindzicz M., Malcolm S., Hu C.C., Allison J.,Winyard P.J., Gullett A.M., Thomas D.F., Belk R.A., Feather S.A., SunT.T., Woolf A.S.: De novo uroplakin IIIa heterozygous mutations causehuman renal adysplasia leading to severe kidney failure. J. Am. Soc.Nephrol., 2005; 16: 2141-2149
  Google Scholar
• 34. Jenkins D., Woolf A.S.: Uroplakins: new molecular players in thebiology of urinary tract malformations. Kidney Int., 2007; 71: 195-200
  Google Scholar
• 35. Jiang S., Gitlin J., Deng F.M., Liang F.X., Lee A., Atala A., Bauer S.B.,Ehrlich G.D., Feather S.A., Goldberg J.D., Goodship J.A., Goodship T.H.,Hermanns M., Hu F.Z., Jones K.E. i wsp.: Lack of major involvementof human uroplakin genes in vesicoureteral reflux: implications fordisease heterogeneity. Kidney Int., 2004; 66: 10-19
  Google Scholar
• 36. Jiang X., Abgottspon D., Kleeb S., Rabbani S., Scharenberg M.,Wittwer M., Haug M., Schwardt O., Ernst B.: Antiadhesion therapyfor urinary tract infections – a balanced PK/PD profile proved to bekey for success. J. Med. Chem., 2012; 55: 4700-4713
  Google Scholar
• 37. Justice S.S., Hung C., Theriot J.A., Fletcher D.A., Anderson G.G.,Footer M.J., Hultgren S.J.: Differentiation and developmental pathwaysof uropathogenic Escherichia coli in urinary tract pathogenesis.Proc. Natl. Acad. Sci. USA, 2004; 101: 1333-1338
  Google Scholar
• 38. Kaufmann O., Volmerig J., Dietel M.: Uroplakin III is a highlyspecific and moderately sensitive immunohistochemical markerfor primary and metastatic urothelial carcinomas. Am. J. Clin. Pathol.,2000; 113: 683-687
  Google Scholar
• 39. Khandelwal P., Abraham S.N., Apodaca G.: Cell biology and physiologyof the uroepithelium. Am. J. Physiol. Renal Physiol., 2009;297: F1477-F1501
  Google Scholar
• 40. Khandelwal P., Prakasam H.S., Clayton D.R., Ruiz W.G., Gallo L.I.,van Roekel D., Lukianov S., Peränen J., Goldenring J.R., Apodaca G.:A Rab11a-Rab8a-Myo5B network promotes stretch-regulated exocytosisin bladder umbrella cells. Mol. Biol. Cell, 2013; 24: 1007-1019
  Google Scholar
• 41. Kong K.L., Kwong D.L., Fu L., Chan T.H., Chen L., Liu H., Li Y., ZhuY.H., Bi J., Qin Y.R., Law S.Y., Guan X.Y.: Characterization of a candidatetumor suppressor gene uroplakin 1A in esophageal squamouscell carcinoma. Cancer Res., 2010; 70: 8832-8841
  Google Scholar
• 42. Kong X.T., Deng F.M., Hu P., Liang F.X., Zhou G., Auerbach A.B.,Genieser N., Nelson P.K., Robbins E.S., Shapiro E., Kachar B., Sun T.T.:Roles of uroplakins in plaque formation, umbrella cell enlargement,and urinary tract diseases. J. Cell Biol., 2004; 167: 1195-1204
  Google Scholar
• 43. Kreft M.E., Hudoklin S., Jezernik K., Romih R.: Formation andmaintenance of blood-urine barrier in urothelium. Protoplasma,2010; 246: 3-14
  Google Scholar
• 44. Kreft M.E., Romih R., Kreft M., Jezernik K.: Endocytotic activityof bladder superficial urothelial cells is inversely related to theirdifferentiation stage. Differentiation, 2009; 77: 48-59
  Google Scholar
• 45. Kreft M.E., Sterle M., Veranic P., Jezernik K.: Urothelial injuriesand the early wound healing response: tight junctions and urothelialcytodifferentiation. Histochem. Cell Biol., 2005; 123: 529-539
  Google Scholar
• 46. Kunju L.P., Mehra R., Snyder M., Shah R.B.: Prostate-specificantigen, high-molecular-weight cytokeratin (clone 34βE12), and/orp63: an optimal immunohistochemical panel to distinguish poorlydifferentiated prostate adenocarcinoma from urothelial carcinoma.Am. J. Clin. Pathol., 2006; 125: 675-681
  Google Scholar
• 47. Kurahashi T., Hara I., Oka N., Kamidono S., Eto H., Miyake H.:Detection of micrometastases in pelvic lymph nodes in patientsundergoing radical cystectomy for locally invasive bladder cancerby real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakinII. Clin. Cancer Res., 2005; 11: 3773-3777
  Google Scholar
• 48. Kurimura Y., Nishitani C., Ariki S., Saito A., Hasegawa Y., TakahashiM., Hashimoto J., Takahashi S., Tsukamoto T., Kuroki Y.: Surfactantprotein D inhibits adherence of uropathogenic Escherichiacoli to the bladder epithelial cells and the bacterium-induced cytotoxicity:a possible function in urinary tract. J. Biol. Chem., 2012;287: 39578-39588
  Google Scholar
• 49. Lai Y., Ye J., Chen J., Zhang L., Wasi L., He Z., Zhou L., Li H., YanQ., Gui Y., Cai Z., Wang X., Guan Z.: UPK3A: a promising novel urinarymarker for the detection of bladder cancer. Urology, 2010; 76:514.e6-e11
  Google Scholar
• 50. Langermann S., Palaszynski S., Barnhart M., Auguste G., PinknerJ.S., Burlein J., Barren P., Koenig S., Leath S., Jones C.H., Hultgren S.J.:Prevention of mucosal Escherichia coli infection by FimH-adhesin-basedsystemic vaccination. Science, 1997; 276: 607-611
  Google Scholar
• 51. Lee G.: Uroplakins in the lower urinary tract. Int. Neurourol.J., 2011; 15: 4-12
  Google Scholar
• 52. Lewis S.A.: Everything you wanted to know about the bladderepithelium but were afraid to ask. Am. J. Physiol. Renal Physiol.,2000; 278: F867-F874
  Google Scholar
• 53. Lewis S.A., de Moura J.L.: Incorporation of cytoplasmic vesiclesinto apical membrane of mammalian urinary bladder epithelium.Nature, 1982; 297: 685-688
  Google Scholar
• 54. Li S.M., Zhang Z.T., Chan S., McLenan O., Dixon C., Taneja S., LeporH., Sun T.T., Wu X.R.: Detection of circulating uroplakin-positivecells in patients with transitional cell carcinoma of the bladder. J.Urol., 1999; 162: 931-935
  Google Scholar
• 55. Liang F.X., Bosland M.C., Huang H., Romih R., Baptiste S., DengF.M., Wu X.R., Shapiro E., Sun T.T.: Cellular basis of urothelial squamousmetaplasia: roles of lineage heterogeneity and cell replacement.J. Cell Biol., 2005; 171: 835-844
  Google Scholar
• 56. Lin J.H., Wu X.R., Kreibich G., Sun T.T.: Precursor sequence,processing, and urothelium-specific expression of a major 15-kDaprotein subunit of asymmetric unit membrane. J. Biol. Chem., 1994;269: 1775-1784
  Google Scholar
• 57. Litwin M.S., Saigal C.S., Yano E.M., Avila C., Geschwind S.A., HanleyJ.M., Joyce G.F., Madison R., Pace J., Polich S.M., Wang M.: Urologicdiseases in America Project: analytical methods and principalfindings. J. Urol., 2005; 173: 933-937
  Google Scholar
• 58. Lobban E.D., Smith B.A., Hall G.D., Harnden P., Roberts P., Selby P.J.,Trejdosiewicz L.K., Southgate J.: Uroplakin gene expression by normaland neoplastic human urothelium. Am. J. Pathol., 1998; 153: 1957-1967
  Google Scholar
• 59. Mahbub Hasan A.K., Sato K., Sakakibara K., Ou Z., Iwasaki T.,Ueda Y., Fukami Y.: Uroplakin III, a novel Src substrate in Xenopusegg rafts, is a target for sperm protease essential for fertilization.Dev. Biol., 2005; 286: 483-492
  Google Scholar
• 60. Matsumoto K., Satoh T., Irie A., Ishii J., Kuwao S., Iwamura M.,Baba S.: Loss expression of uroplakin III is associated with clinicopathologicfeatures of aggressive bladder cancer. Urology, 2008;72: 444-449
  Google Scholar
• 61. Meiland R., Geerlings S.E., Langermann S., Brouwer E.C., CoenjaertsF.E., Hoepelman A.I.: Fimch antiserum inhibits the adherenceof Escherichia coli to cells collected by voided urine specimens ofdiabetic women. J. Urol., 2004; 171: 1589-1593
  Google Scholar
• 62. Mhawech P., Uchida T., Pelte M.F.: Immunohistochemical profileof high-grade urothelial bladder carcinoma and prostate adenocarcinoma.Hum. Pathol., 2002; 33: 1136-1140
  Google Scholar
• 63. Min G., Stolz M., Zhou G., Liang F., Sebbel P., Stoffler D., GlockshuberR., Sun T.T., Aebi U., Kong X.P.: Localization of uroplakin Ia,the urothelial receptor for bacterial adhesin FimH, on the six innerdomains of the 16 nm urothelial plaque particle. J. Mol. Biol., 2002;317: 697-706
  Google Scholar
• 64. Min G., Wang H., Sun T.T., Kong X.P.: Structural basis for tetraspaninfunctions as revealed by the cryo-EM structure of uroplakincomplexes at 6-A resolution. J. Cell Biol., 2006; 173: 975-983
  Google Scholar
• 65. Min G., Zhou G., Schapira M,. Sun T.T., Kong X.P.: Structural basisof urothelial permeability barrier function as revealed by Cryo–EM studies of the 16 nm uroplakin particle. J. Cell Sci., 2003; 116:4087-4094
  Google Scholar
• 66. Mitra S., Lukianov S., Ruiz W.G., Cianciolo Cosentino C., SankerS., Traub L.M., Hukriede N.A., Apodaca G.: Requirement for a uroplakin3a-like protein in the development of zebrafish pronephrictubule epithelial cell function, morphogenesis, and polarity. PLoSOne, 2012; 7: e41816
  Google Scholar
• 67. Mo L., Zhu X.H., Huang H.Y., Shapiro E., Hasty D.L., Wu X.R.:Ablation of the Tamm-Horsfall protein gene increases susceptibilityof mice to bladder colonization by type 1-fimbriated Escherichia coli.Am. J. Physiol. Renal Physiol., 2004; 286: F795-F802
  Google Scholar
• 68. Moad M., Pal D., Hepburn A.C., Williamson S.C., Wilson L., LakoM., Armstrong L., Hayward S.W., Franco O.E., Cates J.M., FordhamS.E., Przyborski S., Carr-Wilkinson J., Robson C.N., Heer R.: A novelmodel of urinary tract differentiation, tissue regeneration, and disease:reprogramming human prostate and bladder cells into inducedpluripotent stem cells. Eur. Urol., 2013; 64: 753-761
  Google Scholar
• 69. Moll R., Wu X.R., Lin J.H., Sun T.T.: Uroplakins, specific membraneproteins of urothelial umbrella cells, as histological markersof metastatic transitional cell carcinomas. Am. J. Pathol., 1995; 147:1383-1397
  Google Scholar
• 70. Mulvey M.A., Lopez-Boado Y.S., Wilson C.L., Roth R., ParksW.C., Heuser J., Hultgren S.J.: Induction and evasion of host defensesby type 1-piliated uropathogenic Escherichia coli. Science, 1998;282: 1494-1497
  Google Scholar
• 71. Mulvey M.A., Schilling J.D., Hultgren S.J.: Establishment of a persistentEscherichia coli reservoir during the acute phase of a bladderinfection. Infect. Immun., 2001; 69: 4572-4579
  Google Scholar
• 72. Negrete H.O., Lavelle J.P., Berg J., Lewis S.A., Zeidel M.L.: Permeabilityproperties of the intact mammalian bladder epithelium. Am.J. Physiol., 1996; 271: F886-F894
  Google Scholar
• 73. Ofek I., Hasty D.L., Abraham S.N., Sharon N.: Role of bacteriallectins in urinary tract infections. Molecular mechanisms for diversificationof bacterial surface lectins. Adv. Exp. Med. Biol., 2000;485: 183-192
  Google Scholar
• 74. Ohtsuka Y., Kawakami S., Fujii Y., Koga F., Saito K., Ando N.,Takizawa T., Kageyama Y., Kihara K.: Loss of uroplakin III expressionis associated with a poor prognosis in patients with urothelialcarcinoma of the upper urinary tract. BJU Int., 2006; 97: 1322-1326
  Google Scholar
• 75. Okegawa T., Kinjo M., Nutahara K., Higashihara E.: Value of reversetranscription polymerase chain assay in peripheral blood ofpatients with urothelial cancer. J. Urol., 2004; 171: 1461-1466
  Google Scholar
• 76. Olsburgh J., Harnden P., Weeks R., Smith B., Joyce A., Hall G.,Poulsom R., Selby P., Southgate J.: Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J. Pathol.,2003; 199: 41-49
  Google Scholar
• 77. Osman I., Kang M., Lee A., Deng F.M., Polsky D., Mikhail M.,Chang C., David D.A., Mitra N., Wu X.R., Sun T.T., Bajorin D.F.: Detectionof circulating cancer cells expressing uroplakins and epidermalgrowth factor receptor in bladder cancer patients. Int. J. Cancer,2004; 111: 934-939
  Google Scholar
• 78. Pak J., Pu Y., Zhang Z.T., Hasty D.L., Wu X.R.: Tamm-Horsfallprotein binds to type 1 fimbriated Escherichia coli and prevents E.coli from binding to uroplakin Ia and Ib receptors. J. Biol. Chem.,2001; 276: 9924-9930
  Google Scholar
• 79. Parker D.C., Folpe A.L., Bell J., Oliva E., Young R.H., Cohen C.,Amin M.B.: Potential utility of uroplakin III, thrombomodulin, highmolecular weight cytokeratin, and cytokeratin 20 in noninvasive,invasive, and metastatic urothelial (transitional cell) carcinomas.Am. J. Surg. Pathol., 2003; 27: 1-10
  Google Scholar
• 80. Riedel I., Liang F.X., Deng F.M., Tu L., Kreibich G., Wu X.R., SunT.T., Hergt M., Moll R.: Urothelial umbrella cells of human ureterare heterogeneous with respect to their uroplakin composition:different degrees of urothelial maturity in ureter and bladder? Eur.J. Cell Biol., 2005; 84: 393-405
  Google Scholar
• 81. Roberts J.A., Marklund B.I., Ilver D., Haslam D., Kaack M.B., BaskinG., Louis M., Möllby R., Winberg J., Normark S.: The Gal(α 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed forpyelonephritis to occur in the normal urinary tract. Proc. Natl. Acad.Sci. USA, 1994; 91: 11889-11893
  Google Scholar
• 82. Romih R., Jezernik K., Mašera A.: Uroplakins and cytokeratins inthe regenerating rat urothelium after sodium saccharin treatment.Histochem. Cell Biol., 1998; 109: 263-269
  Google Scholar
• 83. Romih R., Korošec P., de Mello W.Jr., Jezernik K.: Differentiation ofepithelial cells in the urinary tract. Cell Tissue Res., 2005; 320: 259-268
  Google Scholar
• 84. Sakakibara K., Sato K., Yoshino K., Oshiro N., Hirahara S., MahbubHasan A.K., Iwasaki T., Ueda Y., Iwao Y., Yonezawa K., FukamiY.: Molecular identification and characterization of Xenopus egguroplakin III, an egg raft-associated transmembrane protein thatis tyrosine-phosphorylated upon fertilization. J. Biol. Chem., 2005;280: 15029-15037
  Google Scholar
• 85. Sano T., Hamada S., Haitani T., Nakashima M., Kajita Y., ShichiriY.: Lung metastasis of ta bladder cancer: a case report and literaturereview. Korean J. Urol., 2013; 54: 271-273
  Google Scholar
• 86. Schönfelder E.M., Knüppel T., Tasic V., Miljkovic P., Konrad M.,Wühl E., Antignac C., Bakkaloglu A., Schaefer F., Weber S.: Mutationsin Uroplakin IIIA are a rare cause of renal hypodysplasia in humans.Am. J. Kidney Dis., 2006; 47: 1004-1012
  Google Scholar
• 87. Scott J.E.: Fetal, perinatal, and infant death with congenital renalanomaly. Arch. Dis. Child., 2002; 87: 114-117
  Google Scholar
• 88. Smith S.C., Mohanty S.K., Kunju L.P., Chang E., Chung F., CarvalhoJ.C., Paner G.P., Hansel D.E., Luthringer D.J., de Peralta-VentrurinaM.N., Amin M.B.: Uroplakin II outperforms uroplakin III indiagnostically challenging settings. Histopathology, 2014; 65: 132-138
  Google Scholar
• 89. Sokurenko E.V., Chesnokova V., Dykhuizen D.E., Ofek I., Wu X.R.,Krogfelt K.A., Struve C., Schembri M.A., Hasty D.L.: Pathogenic adaptationof Escherichia coli by natural variation of the FimH adhesin.Proc. Natl. Acad. Sci. USA, 1998; 95: 8922-8926
  Google Scholar
• 90. Sun T.T., Zhao H., Provet J., Aebi U., Wu X.R.: Formation of asymmetricunit membrane during urothelial differentiation. Mol. Biol.Rep., 1996; 23: 3-11
  Google Scholar
• 91. Taganna J., de Boer A.R., Wuhrer M., Bouckaert J.: Glycosylationchanges as important factors for the susceptibility to urinary tractinfection. Biochem. Soc. Trans., 2011; 39: 349-354
  Google Scholar
• 92. Thumbikat P., Berry R.E., Schaeffer A.J., Klumpp D.J.: Differentiation-induceduroplakin III expression promotes urothelial cell deathin response to uropathogenic E. coli. Microbes Infect., 2009; 11: 57-65
  Google Scholar
• 93. Thumbikat P., Berry R.E., Zhou G., Billips B.K., Yaggie R.E., ZaichukT., Sun T.T., Schaeffer A.J., Klumpp D.J.: Bacteria-induced uroplakinsignaling mediates bladder response to infection. PLoS Pathog.,2009; 5: e1000415
  Google Scholar
• 94. Truong L.D., Shen S.S.: Immunohistochemical diagnosis of renalneoplasms. Arch. Pathol. Lab. Med., 2011; 135: 92-109
  Google Scholar
• 95. Tu L., Kong X.P., Sun T.T., Kreibich G.: Integrity of all four transmembranedomains of the tetraspanin uroplakin Ib is required forits exit from the ER. J. Cell Sci., 2006; 119: 5077-5086
  Google Scholar
• 96. Varley C.L., Bacon E.J., Holder J.C., Southgate J.: FOXA1 and IRF-1intermediary transcriptional regulators of PPARg-induced urothelialcytodifferentiation. Cell Death Differ., 2009; 16: 103-114
  Google Scholar
• 97. Veranic P., Romih R., Jezernik K.: What determines differentiationof urothelial umbrella cells? Eur. J. Cell Biol., 2004; 83: 27-34
  Google Scholar
• 98. Wang D., Wang Z., Tian J., He X., Chowdhury W.H., Zhang X., LiS., Rodriguez R.: Prostate stem cell antigen enhancer and uroplakinII promoter based bladder cancer targeted tissue-specific vector.Urol. Oncol., 2010; 28: 164-169
  Google Scholar
• 99. Wang H., Min G., Glockshuber R., Sun T.T., Kong X.P.: UropathogenicE. coli adhesin-induced host cell receptor conformationalchanges: implications in transmembrane signaling transduction. J.Mol. Biol., 2009; 392: 352-361
  Google Scholar
• 100. Weber S.: Novel genetic aspects of congenital anomalies of kidneyand urinary tract. Curr. Opin. Pediatr., 2012; 24: 212-218
  Google Scholar
• 101. Wellens A., Garofalo C., Nguyen H., Van Gerven N., SlättegårdR., Hernalsteens J.P., Wyns L., Oscarson S., De Greve H., Hultgren S.,Bouckaert J.: Intervening with urinary tract infections using anti–adhesives based on the crystal structure of the FimH-oligomannose-3complex. PLoS One, 2008; 3: e2040
  Google Scholar
• 102. Wroński S.: Śródmiąższowe zapalenie pęcherza moczowego.Etiologia, diagnostyka, leczenie. Nowa Med. 5/2000 http://www.czytelniamedyczna.pl/1651,Srodmiazszowe-zapalenie-pecherzamoczowego-etiologia-diagnostyka-leczenie.html
  Google Scholar
• 103. Wu R.L., Osman I., Wu X.R., Lu M.L., Zhang Z.F., Liang F.X.,Hamza R., Scher H., Cordon-Cardo C., Sun T.T.: Uroplakin II gene isexpressed in transitional cell carcinoma but not in bilharzial bladdersquamous cell carcinoma: alternative pathways of bladder epithelialdifferentiation and tumor formation. Cancer Res., 1998; 58:1291-1297
  Google Scholar
• 104. Wu X., Kakehi Y., Zeng Y., Taoka R., Tsunemori H., Inui M.:Uroplakin II as a promising marker for molecular diagnosis of nodalmetastases from bladder cancer: comparison with cytokeratin 20. J.Urol., 2005; 174: 2138-2142
  Google Scholar
• 105. Wu X.R., Kong X.P., Pellicer A., Kreibich G., Sun T.T.: Uroplakinsin urothelial biology, function, and disease. Kidney Int., 2009;75: 1153-1165
  Google Scholar
• 106. Wu X.R., Lin J.H., Walz T., Häner M., Yu J., Aebi U., Sun T.T.:Mammalian uroplakins. A group of highly conserved urothelial differentiation-relatedmembrane proteins. J. Biol. Chem., 1994; 269:13716-13724
  Google Scholar
• 107. Wu X.R., Manabe M., Yu J., Sun T.T.: Large scale purificationand immunolocalization of bovine uroplakins I, II, and III. Molecularmarkers of urothelial differentiation. J. Biol. Chem., 1990; 265:19170-19179
  Google Scholar
• 108. Wu X.R., Sun T.T.: Molecular cloning of a 47 kDa tissue-specificand differentiation-dependent urothelial cell surface glycoprotein.J. Cell Sci., 1993; 106: 31-43
  Google Scholar
• 109. Wu X.R., Sun T.T., Medina J.J.: In vitro binding of type 1-fimbriatedEscherichia coli to uroplakins Ia and Ib: relation to urinary tractinfections. Proc. Natl. Acad. Sci. USA, 1996; 93: 9630-9635
  Google Scholar
• 110. Xie B., Zhou G., Chan S.Y., Shapiro E., Kong X.P., Wu X.R., SunT.T., Costello C.E.: Distinct glycan structures of uroplakins Ia and Ib: structural basis for the selective binding of FimH adhesin to uroplakinIa. J. Biol. Chem., 2006; 281: 14644-14653
  Google Scholar
• 111. Yu W., Hill W.G.: Defining protein expression in the urothelium:a problem of more than transitional interest. Am. J. Physiol. RenalPhysiol., 2011; 301: F932-F942
  Google Scholar
• 112. Yu Z., Mannik J., Soto A., Lin K.K., Andersen B.: The epidermaldifferentiation-associated Grainyhead gene Get1/Grhl3 also regulatesurothelial differentiation. EMBO J., 2009; 28: 1890-1903
  Google Scholar
• 113. Yuasa T., Yoshiki T., Isono T., Tanaka T., Hayashida H., OkadaY.: Expression of transitional cell-specific genes, uroplakin Ia andII, in bladder cancer: detection of circulating cancer cells in the peripheralblood of metastatic patients. Int. J. Urol., 1999; 6: 286-292
  Google Scholar
• 114. Yuasa T., Yoshiki T., Isono T., Tanaka T., Okada Y.: Molecularcloning and expression of uroplakins in transitional cell carcinoma.Adv. Exp. Med. Biol., 2003; 539: 33-46
  Google Scholar
• 115. Zhou G., Liang F.X., Romih R., Wang Z., Liao Y., Ghiso J., Luque-GarciaJ.L., Neubert T.A., Kreibich G., Alonso M.A., Schaeren–Wiemers N., Sun T.T.: MAL facilitates the incorporation of exocyticuroplakin-delivering vesicles into the apical membrane of urothelialumbrella cells. Mol. Biol. Cell, 2012; 23: 1354-1366
  Google Scholar
• 116. Zhou G., Mo W.J., Sebbel P., Min G., Neubert T.A., GlockshuberR., Wu X.R., Sun T.T., Kong X.P.: Uroplakin Ia is the urothelial receptorfor uropathogenic Escherichia coli: evidence from in vitro FimHbinding. J. Cell Sci., 2001; 114: 4095-4103
  Google Scholar
• 117. Zhu H.J., Zhang Z.Q., Zeng X.F., Wei S.S., Zhang Z.W., Guo Y.L.:Cloning and analysis of human uroplakin II promoter and its applicationfor gene therapy in bladder cancer. Cancer Gene Ther.,2004; 11: 263-272
  Google Scholar
• 118. Zupančič D., Ovčak Z., Vidmar G., Romih R.: Altered expressionof UPIa, UPIb, UPII, and UPIIIa during urothelial carcinogenesis inducedby N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. VirchowsArch., 2011; 458: 603-613
  Google Scholar
• 119. Zupančič D., Romih R.: Heterogeneity of uroplakin localizationin human normal urothelium, papilloma and papillary carcinoma.Radiol. Oncol., 2013; 47: 338-345
  Google Scholar
• 120. Zupančič D., Zakrajšek M., Zhou G., Romih R.: Expression andlocalization of four uroplakins in urothelial preneoplastic lesions.Histochem. Cell Biol., 2011; 136: 491-500
  Google Scholar

Full text